Contact information
Type
Scientific
Primary contact
Dr Marie-Pierre Preziosi
ORCID ID
Contact details
World Health Organization
20 Avenue Appia
Geneva
CH-1211
Switzerland
+41 (0)22 791 3744
preziosim@who.int
Type
Scientific
Additional contact
Prof Samba Sow
ORCID ID
Contact details
Centre pour les Vaccins en Développement (CVD)
BP 251
Bamako
-
Mali
Type
Scientific
Additional contact
Dr Brown Okoko
ORCID ID
Contact details
PO Box 273
Banjul
Fajara
-
Gambia
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
RPC178
Study information
Scientific title
A phase II, observer-blind, randomised, active controlled study to compare the safety, immunogenicity, and induction of immunological memory of a meningococcal A conjugate vaccine, a meningococcal ACYW polysaccharide vaccine and a hib conjugate vaccine, administered in healthy toddlers 12 - 23 months of age
Acronym
Study hypothesis
The present study is pivotal, designed as a non-inferiority trial to evaluate the immunogenicity and the safety of one dose of 10 µg of PsA-TT vaccine. Immunological memory and persistence of antibodies induced by a single intramuscular injection of the study vaccine will also be evaluated. The immunogenicity will be assessed against that of a licensed meningococcal polysaccharide ACYW vaccine. The three-group design will allow comparison of the PsA-TT vaccine (study vaccine group) safety profile with that of two licensed vaccines: the meningococcal ACYW tetravalent polysaccharide vaccine (Mencevax - reference vaccine group), and the Hib-conjugate vaccine (Hiberix - control vaccine group). The booster study is expected to provide evidence that the PsA-TT conjugate vaccine is able to prime immunological memory. Antibody persistence will be evaluated at eight months (i.e. before the booster dose), one year and two years after the first dose.
Ethics approval
This protocol has been approved by the following institutions:
1. Human Subjects Protection Committee at PATH, USA
2. University of Maryland Baltimore Institutional Review Board (IRB), USA
3. Comité d'Ethique de la Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie, Mali
4. Medical Research Council Scientific Coordinating Committee, The Gambia
5. Medical Research Council Gambia Government Ethics Committee, The Gambia
6. World Health Organization (WHO) Research Ethics Review Committee
Study design
Phase II observer-blind randomised active-controlled study
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Prevention
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Condition
Meningococcal A disease
Intervention
The intervention is vaccination at day zero of one of the three vaccines: study vaccine, reference vaccine (Mencevax) or control vaccine (Hiberix) , followed by a booster vaccination 32 weeks later with one of the three vaccines, study vaccine, reference vaccine (1/5th of a dose) or control vaccine. Subjects will be randomised in a 1:1:1 ratio.
Intervention type
Biological/Vaccine
Phase
Drug names
Primary outcome measures
The percentage of subjects who show a seroconversion for anti-Meningococcal Polysaccharide A (MenPsA) antibodies, i.e. a four-fold increase in post-immunisation serum titre with respect to pre-immunisation serum titre, at 28 days after a single vaccine dose, as measured by rank Signaling Block Age (rSBA) assay.
Secondary outcome measures
1. The percentage of subjects with local and systemic adverse events, including solicited adverse reactions and events, and Serious Adverse Events (SAEs), as measured at four and 28 days after the primary vaccination (reactogenicity and short-term safety)
2. The percentage of subjects with local and systemic adverse events, including solicited adverse reactions and events, and SAEs, as measured at four and 28 days after the booster vaccination (reactogenicity and short-term safety)
3. The percentage of subjects who show a seroconversion for anti-MenPsA total Immunoglobulin G (IgG), i.e. a two-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration, at 28 days after a single vaccine dose, as measured by the Enzyme-Linked ImmunoadSorbent Assay (ELISA). The percentage of subjects with a four-fold increase in post-immunisation serum concentration with respect to pre-immunisation serum concentration will be also considered
Overall trial start date
28/08/2006
Overall trial end date
28/11/2008
Reason abandoned
Eligibility
Participant inclusion criteria
1. Age 12 to 23 months of age (both included)
2. Written informed consent obtained from the mother, father, or guardian of the child
3. Free of obvious health problems as established by medical history including physical examination and clinical judgment of the investigator
4. Mother, father, or guardian capable and willing to bring their child or to receive home visits for their child for all follow-up visits
5. Residence in the study area
6. Fully vaccinated according to local Expanded Program on Immunisation (EPI) schedule
Participant type
Patient
Age group
Child
Gender
Both
Target number of participants
600
Participant exclusion criteria
1. Previous vaccination against serogroup A Neisseria meningitidis
2. Known exposure to serogroup A Neisseria meningitidis during the three previous months
3. History of allergic disease or known hypersensitivity to any component of the three study vaccines
4. History of Serious Adverse Reactions (SAR) following administration of vaccines included in the local program of immunization
5. Administration of any other vaccine within 60 days prior to administration of study vaccines or planned vaccination during the first four weeks after the study vaccination
6. Use of any investigational or non-registered drug within 90 days prior to the administration of study vaccines
7. Administration of immunoglobulins and/or any blood products since birth or planned administration during the vaccine period
8. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents since birth (including systemic or inhaled corticosteroids, this means prednisone or equivalent, 0.5 mg/kg/day [topical steroids are allowed])
9. A family history of congenital or hereditary immunodeficiency
10. History of meningitis or seizures or any neurological disorder
11. Major congenital defects or serious chronic illness, including malnutrition (as per investigator's judgment)
12. Acute disease at the time of enrolment (acute disease is defined as the presence of a moderate or severe illness with or without fever) is a temporary exclusion
13. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination or laboratory tests, which in the opinion of the investigator, might interfere with the study objectives
14. Any condition or criteria that in the opinion of the investigator might compromise the well being of the subject or the compliance with study procedures or interfere with the outcome of the study
15. Non-residence in the study area or intent to move out within one year
Recruitment start date
28/08/2006
Recruitment end date
28/11/2008
Locations
Countries of recruitment
Gambia, Mali
Trial participating centre
World Health Organization
Geneva
CH-1211
Switzerland
Sponsor information
Organisation
Serum Institute of India Limited (SIIL)
Sponsor details
212/2
Hadapsar
Pune
411028
India
Sponsor type
Research organisation
Website
Organisation
Program for Appropriate Technology in Health (PATH)
Sponsor details
1455 NW Leary Way
Seattle
WA 98107
United States of America
Sponsor type
Research organisation
Website
Funders
Funder type
Charity
Funder name
Bill and Melinda Gates Foundation
Alternative name(s)
Bill & Melinda Gates Foundation
Funding Body Type
private sector organisation
Funding Body Subtype
foundation
Location
United States of America
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21675889
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553690
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553689
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553685
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553683
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553670
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/26553669
Publication citations
-
Results
Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP, Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans., N. Engl. J. Med., 2011, 364, 24, 2293-2304, doi: 10.1056/NEJMoa1003812.
-
Results
Borrow R, Tang Y, Yakubu A, Kulkarni PS, LaForce FM, MenAfriVac as an Antitetanus Vaccine, Clin Infect Dis, 2015 , 61 , Suppl 5, S570-S577, doi: 10.1093/cid/civ512.
-
Results
Holme D, Findlow H, Sow SO, Idoko OT, Preziosi MP, Carlone G, Plikaytis BD, Borrow R, Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination, Clin Infect Dis, 2015 , 61, Suppl 5, S563-S569, doi: 10.1093/cid/civ505.
-
Results
Tang Y, Plikaytis BD, Preziosi MP, Borrow R, Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac, Clin Infect Dis, 2015 , 61, Suppl 5, S531-S539, doi: 10.1093/cid/civ601.
-
Results
Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R, Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age, Clin Infect Dis, 2015 , 61 , Suppl 5, S514-S520, doi: 10.1093/cid/civ672.
-
Results
Martellet L, Sow SO, Diallo A, Hodgson A, Kampmann B, Hirve S, Tapia M, Haidara FC, Ndiaye A, Diarra B, Ansah PO, Akinsola A, Idoko OT, Adegbola RA, Bavdekar A, Juvekar S, Viviani S, Enwere GC, Marchetti E, Chaumont J, Makadi MF, Pallardy F, Kulkarni PS, Preziosi MP, LaForce FM, Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine, Clin Infect Dis, 2015 , 61 , Suppl 5, S422-S427, doi: 10.1093/cid/civ598.
-
Results
Idoko OT, Diallo A, Sow SO, Hodgson A, Akinsola A, Diarra B, Haidara FC, Ansah PO, Kampmann B, Bouma E, Preziosi MP, Enwere GC, Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials, Clin Infect Dis, 2015 , 61 , Suppl 5, S416-S421, doi: 10.1093/cid/civ596.